GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akcea Therapeutics Inc (NAS:AKCA) » Definitions » Equity-to-Asset

Akcea Therapeutics (Akcea Therapeutics) Equity-to-Asset : 0.91 (As of Jun. 2020)


View and export this data going back to 2017. Start your Free Trial

What is Akcea Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Akcea Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2020 was $479.0 Mil. Akcea Therapeutics's Total Assets for the quarter that ended in Jun. 2020 was $527.9 Mil. Therefore, Akcea Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2020 was 0.91.

The historical rank and industry rank for Akcea Therapeutics's Equity-to-Asset or its related term are showing as below:

AKCA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.67   Med: 0.75   Max: 0.91
Current: 0.91

During the past 6 years, the highest Equity to Asset Ratio of Akcea Therapeutics was 0.91. The lowest was -0.67. And the median was 0.75.

AKCA's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.66 vs AKCA: 0.91

Akcea Therapeutics Equity-to-Asset Historical Data

The historical data trend for Akcea Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akcea Therapeutics Equity-to-Asset Chart

Akcea Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Equity-to-Asset
Get a 7-Day Free Trial 0.84 -1.66 0.62 0.76 0.91

Akcea Therapeutics Quarterly Data
Dec14 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.85 0.91 0.91 0.91

Competitive Comparison of Akcea Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Akcea Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akcea Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akcea Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Akcea Therapeutics's Equity-to-Asset falls into.



Akcea Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Akcea Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Equity to Asset (A: Dec. 2019 )=Total Stockholders Equity/Total Assets
=543.004/599.25
=0.91

Akcea Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2020 is calculated as

Equity to Asset (Q: Jun. 2020 )=Total Stockholders Equity/Total Assets
=479.028/527.937
=0.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akcea Therapeutics  (NAS:AKCA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Akcea Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Akcea Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Akcea Therapeutics (Akcea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 9th Floor, Boston, MA, USA, 02110
Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.
Executives
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Joshua F. Patterson officer: General Counsel C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Damien Mcdevitt director, officer: Chief Executive Officer C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Alex G. Howarth officer: Chief Operating Officer C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Kyle Jenne officer: Chief Commercial Officer C/O AKCEA THERAPEUTICS, INC. 22 BOSTON WHARF ROAD, 9TH FLOOR BOSTON MA 02210
William T. Andrews officer: Chief Medical Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Michael Dennis Price officer: Chief Financial Officer
Elaine Hochberg director C/O AKCEA THERAPAEUTICS 55 CAMBRIDGE PKWY, STE 100 CAMBRIDGE MA 02142
Isis Pharmaceuticals Inc 10 percent owner 2855 GAZELLE COURT, CARLSBAD CA 92010
Michael F Maclean officer: Chief Financial Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Paula Soteropoulos director, officer: Chief Executive Officer 49 WINONA STREET, PEABODY MA 01960

Akcea Therapeutics (Akcea Therapeutics) Headlines

From GuruFocus